Zevra Therapeutics, Inc. (ZVRA)

Market Cap	196.29M
Revenue (ttm)	27.46M
Net Income (ttm)	-46.05M
Shares Out	43.43M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,571
Open	4.490
Previous Close	4.500
Day's Range	4.390 - 4.630
52-Week Range	3.890 - 7.280
Beta	1.84
Analysts	Strong Buy
Price Target	20.00 (+342.48%)
Earnings Date	May 13, 2024

About ZVRA

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2015
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ZVRA

Financial Performance

In 2023, ZVRA's revenue was $27.46 million, an increase of 170.26% compared to the previous year's $10.16 million. Losses were -$46.05 million, 72.0% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 342.48% from the latest price.

Price Target

$20.0

(342.48% upside)

Analyst Consensus: Strong Buy